NCT03217747 2025-10-23Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting173 enrolled 28 charts
NCT02315066 2022-04-21Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566PfizerPhase 1 Completed174 enrolled 68 charts